Biblio Discovery — Demo Discovery Service

21 results for "Drew Provan"

Showing 1–20 · 0.01 seconds · RSS

  1. Journal Article

    Recent advances in the mechanisms and treatment of immune thrombocytopenia

    Drew Provan; John W. Semple

    EBioMedicine, Vol. 76 · 2022 · English · DOAJ Scopus

    Summary: Primary immune thrombocytopenia is an autoimmune disease associated with a reduced peripheral blood platelet count. The phenotype is variable with some patients suffering no bleeding whilst others have severe bleeding which may be fatal. Variability in clinical behaviour and treatment…

  2. Journal Article Full text

    Sustained Remission Off-Treatment (SROT) of TPO-RAs: The Burgos Ten-Step Eltrombopag Tapering Scheme

    Tomás José González-López; Drew Provan

    Medicina, Vol. 59 No. 4 · 2023 · English · DOAJ Scopus

    Background and Objectives: TPO-RAs (romiplostim/eltrombopag/avatrombopag) have broadly demonstrated high efficacy rates (59–88%), durable responses (up to three years) and a satisfactory safety profile in clinical trials. The effect of TPO-RAs is classically considered to be transient because…

  3. Journal Article Full text

    Current Concepts in the Diagnosis and Management of Adult Primary Immune Thrombocytopenia: Our Personal View

    Tomás José González-López; Adrian Newland; Drew Provan

    Medicina, Vol. 59 No. 4 · 2023 · English · DOAJ Scopus

    Primary immune thrombocytopenia (ITP) is an acquired blood disorder that causes a reduction in circulating platelets with the potential for bleeding. The incidence of ITP is slightly higher in adults and affects more women than men until 60 years, when males are more affected. Despite advances in…

  4. Journal Article

    Immune thrombocytopenia: Modern management, knowledge gaps, and future perspectives

    Waleed Ghanima; Lamya Garabet; Rick Kapur et al.

    Iraqi Journal of Hematology, Vol. 14 No. 2 · 2025 · English · DOAJ Scopus

    Immune thrombocytopenia (ITP) is an autoimmune disorder with increased risk of bleeding due to a low number of platelets. The pathophysiology is complex and not fully understood, but platelet autoantibodies and/or CD8+ T-cells are responsible, via diverse mechanisms, for disrupting platelet…

  5. Journal Article

    Authors' Response to Zimmer et al

    Roberto Stasi; Sergio Amadori; John Osborn et al.

    PLoS Medicine, Vol. 3 No. 8 · 2006 · English · DOAJ Scopus

  6. Journal Article

    Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia.

    Roberto Stasi; Sergio Amadori; John Osborn et al.

    PLoS Medicine, Vol. 3 No. 3 · 2006 · English · DOAJ Scopus

    BackgroundThe long-term outcome of individuals with mild degrees of thrombocytopenia is unknown.Methods and findingsIn a prospective study conducted between August 1992 and December 2002, 260 apparently healthy individuals with incidentally discovered platelet counts between 100 x 10(9)/l and 150 x…

  7. Journal Article Full text

    Can Machine Learning Assist in Diagnosis of Primary Immune Thrombocytopenia? A Feasibility Study

    Haroon Miah; Dimitrios Kollias; Giacinto Luca Pedone et al.

    Diagnostics, Vol. 14 No. 13 · 2024 · English · DOAJ Scopus

    Primary Immune Thrombocytopenia (ITP) is a rare autoimmune disease characterised by the immune-mediated destruction of peripheral blood platelets in patients leading to low platelet counts and bleeding. The diagnosis and effective management of ITP are challenging because there is no established…

  8. Journal Article

    Literature Review and Experts’ Opinion for Managing Thrombocytopenia in Chronic Liver Disease

    Faisal Alsayegh; Ahmed Alfadhli; Abeer Algharabally et al.

    Journal of Applied Hematology, Vol. 16 No. 1 · 2025 · English · DOAJ Scopus

    Thrombocytopenia (TCP) commonly complicates chronic liver disease (CLD), with platelet transfusion traditionally serving as the standard therapeutic approach, despite associated risks such as infection, alloimmunization, and transfusion reactions. Recent advancements have introduced thrombopoietin…

  9. Journal Article

    Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults

    Drew Provan; Tom Butler; Maria Laura Evangelista et al.

    Haematologica, Vol. 92 No. 12 · 2007 · English · DOAJ Scopus

    We conducted a retrospective analysis of 11 consecutive patients with various autoimmune cytopenias who failed to respond to conventional treatments and received a fixed-dose regimen of rituximab (100 mg weekly for 4 consecutive weeks). Sustained complete responses were achieved in 4 out of 7…

  10. Journal Article

    Inflammatory cytokines, inflammasomes, and neutrophil extracellular traps in primary immune thrombocytopenia pathogenesis

    Alessandro Lucchesi; Maria Belen Rodriguez; Matias Cordoba et al.

    Blood Vessels, Thrombosis & Hemostasis, Vol. 3 No. 1 · 2026 · English · DOAJ Scopus

    Abstract: Primary immune thrombocytopenia (ITP) is a disorder characterized by enhanced platelet clearance and impaired production due to immune dysregulation. Central to its pathogenesis are platelet autoantibodies, T-cell–mediated processes, and altered cytokine profiles, which exacerbate…

  11. Journal Article

    Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database

    Ameet Sarpatwari; Dimitri Bennett; John W. Logie et al.

    Haematologica, Vol. 95 No. 7 · 2010 · English · DOAJ Scopus

    Background The risk of thromboembolic events in adults with primary immune thrombocytopenia has been little investigated despite findings of increased susceptibility in other thrombocytopenic autoimmune conditions. The objective of this study was to evaluate the risk of thromboembolic events among…

  12. Journal Article

    Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently

    Mohamed A. Yassin; Mona Al-Rasheed; Murtadha Al-Khaboori et al.

    Frontiers in Cardiovascular Medicine, Vol. 10 · 2023 · English · DOAJ Scopus

    IntroductionThrombopoietin-receptor agonist (TPO-RAs) currently represent the state of art for treating immune thrombocytopenia. Their different molecular structures contribute to the difference in their pharmacodynamics and pharmacokinetics. This narrative review aims to provide an overview of the…

  13. Journal Article

    A distinct plasmablast and naïve B-cell phenotype in primary immune thrombocytopenia

    Shaun M. Flint; Adele Gibson; Geoff Lucas et al.

    Haematologica, Vol. 101 No. 6 · 2016 · English · DOAJ Scopus

    Primary immune thrombocytopenia is an autoimmune disorder in which platelet destruction is a consequence of both B- and T-cell dysregulation. Flow cytometry was used to further characterize the B- and T-cell compartments in a cross-sectional cohort of 26 immune thrombocytopenia patients including…

  14. Journal Article

    Concurrent coronary artery disease and immune thrombocytopenia: a systematic review

    Alaa Rahhal; Drew Provan; Khaled Shunnar et al.

    Frontiers in Medicine, Vol. 10 · 2023 · English · DOAJ Scopus

    IntroductionCoronary artery disease (CAD) management in the setting of immune thrombocytopenia (ITP) remains very challenging to clinicians as a reasonable balance between bleeding and thrombosis risks needs to be achieved, and the evidence guiding such management is scarce.MethodsWe conducted a…

  15. Journal Article

    A practical guide to the management of immune thrombocytopenia co-existing with acute coronary syndrome

    Alaa Rahhal; Drew Provan; Waleed Ghanima et al.

    Frontiers in Medicine, Vol. 11 · 2024 · English · DOAJ Scopus

    IntroductionImmune thrombocytopenia (ITP) management with co-existing acute coronary syndrome (ACS) remains challenging as it requires a clinically relevant balance between the risk and outcomes of thrombosis and the risk of bleeding. However, the literature evaluating the treatment approaches in…

  16. Journal Article

    Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia

    Douglas B. Cines; Jeffrey Wasser; Francesco Rodeghiero et al.

    Haematologica, Vol. 102 No. 8 · 2017 · English · DOAJ Scopus

    Primary immune thrombocytopenia is an autoimmune disorder characterized by increased platelet destruction and insufficient platelet production without another identified underlying disorder. Splenectomy may alter responsiveness to treatment and/or increase the risk of thrombosis, infection, and…

  17. Journal Article

    Iraqi consensus recommendations for the diagnosis and management of immune thrombocytopenia

    Ahmed Mjali; Bassam Francis Matti; Waleed Ghanima et al.

    Hematology, Vol. 30 No. 1 · 2025 · English · DOAJ Scopus

    Background and Objectives The management of ITP has evolved with evidence-based international guidelines. However, Iraq’s unique challenges, including variations in clinical practice and treatment disparities, necessitate localized guidance to bridge global recommendations and real-world practice…

  18. Journal Article

    Updated international consensus report on the investigation and management of primary immune thrombocytopenia

    Drew Provan; Donald M. Arnold; James B. Bussel et al.

    Blood Advances, Vol. 3 No. 22 · 2019 · English · DOAJ Scopus

    Abstract: Over the last decade, there have been numerous developments and changes in treatment practices for the management of patients with immune thrombocytopenia (ITP). This article is an update of the International Consensus Report published in 2010. A critical review was performed to identify…